Franck Le Deu retweeted
I recently had the opportunity to discuss BeOne’s global capabilities on Cambridge Associates’ Unseen Upside podcast, including why we invested in building our own global development “superhighway” and what I’ve learned about the power of scientific collaboration across borders.
I hope you’ll listen to the conversation: ow.ly/uFgv5105csv
#UnseenUpside #Oncology #Innovation
Check out my latest article: Trust is the real COIN(s) of the China Biotech Realm linkedin.com/pulse/trust-rea… via @LinkedIn
65
Franck Le Deu retweeted
For Bloomberg News Big Take, a deep dive on how biotech startups and pharma giants are increasingly taking trials to China early — and the new and complex challenges they pose.
with @ashleighfurlong @fabiennekatrin and team:
bloomberg.com/news/features/…
Franck Le Deu retweeted
The U.S. Treasury is proposing new restrictions on investments in Chinese biotech, but traditional pharma licensing deals would largely be spared. Equity investments and certain partnerships could face significant hurdles. fiercebiotech.com/biotech/tr…
Franck Le Deu retweeted
How did Hengrui become a go-to source of Chinese biopharma innovation? After multibillion-dollar deals with BMS and GSK, the company's R&D leader tells Fierce what's driving its success and where it goes next. fiercebiotech.com/biotech/he…
Franck Le Deu retweeted
Roche is doubling down on China's Hansoh Pharma with a new ADC deal worth up to $15 billion in milestones. The pact comes just a year after the companies' first collaboration. fiercebiotech.com/biotech/ro… $ROCH.NE
Pleased to share my latest article written for BioCentury China biopharma still faces a long road to globalization biocentury.com/article/66096…
1
2
78
Europe’s narrow path between the U.S. and China in biotech biocentury.com/article/65981…
I wrote this three months ago for BioCentury. It feels increasingly relevant, between the China 15 FYP for Biopharma, the letter from US CEOs asking Congress not to block China deals, and the letter from European Boards asking European leaders to wake up, or else…
1
110
Check out my latest article: A week in Shanghai - interpreting mixed China biopharma signals linkedin.com/pulse/week-shan… via @LinkedIn
2
155
Franck Le Deu retweeted
« Il faut une première à tout et il faut une dernière pour se souvenir, une dernière, juste pour lui. ❤️ »
Merci à @ligue1plus pour LES ÉMOTIONS sur cette bande-annonce de Brest-PSG avec un hommage pour Éric Roy 🇫🇷. 🥹🕊️
Franck Le Deu retweeted
Listen to Episode 44 of @BioVentureVoiCe video podcast w/ Adam Koppel, Partner at @BainCapital. Adam discusses the evolution of biotech investing from the early days of crossover investing to company creation w/ pharma assets and the current strategies out of Bain Capital's Life Sciences private equity fund. The full video is here on @BiotechTV (and also on Spotify and Apple Podcasts): biotechtv.com/post/adam-kopp…
𝐁𝐢𝐨𝐕𝐞𝐧𝐭𝐮𝐫𝐞 𝐕𝐨𝐢𝐂𝐞𝐬: @BainCapital's Adam Koppel discusses both public and private equity investing in biotech, and how the sector has changed over his years in the space.
Full video: biotechtv.com/post/adam-kopp…
I shared some perspectives on the China biopharma market dynamics in this hour long podcast. chinahealthpulse.com/p/the-c…
1
98
Franck Le Deu retweeted
Thoughtful and detailed comments by Alexis Borisy on the China debate, which he has lived from many angles including EQRx, at our conference this week.
Franck Le Deu retweeted
Hengrui rising: Frank Jiang on building a global biotech. On The BioCentury Show, Jiang discusses Hengrui’s R&D scale, global ambitions, and what its GSK and BMS alliances reveal about the next phase of China-originated innovation. buff.ly/soem45G
Franck Le Deu retweeted
Europe's narrow path between the U.S. and China: Europe has an opening to become biotech's third pole, says Franck Le Deu in a BioCentury Guest Commentary, but only if it engages China while anchoring IP, manufacturing, development at home (open access): biocentury.com/article/65981…
Franck Le Deu retweeted
A écouter. Absolument passionnant pour quiconque s’intéresse à la démographie au moment où nous vivons un phénomène mondial sans précédent : Why birth rates are falling everywhere all at once | FT youtu.be/6lFXmDk-tps?is=FaqR… via @YouTube
Franck Le Deu retweeted
My new essay "A Biopharmaceutical Superpower: China’s Rise, Its Limits, and What Comes Next": China’s biopharma revolution is real: once a generics & API giant, it now controls ~80% of global API intermediates, nearly all KSMs for key U.S. drugs, and is closing the gap on innovative pipelines. Record licensing deals topped $135B last year—Pfizer alone paid $1.25B for a Chinese bispecific. 1/3 cirsd.org/horizon-article/a-…
Franck Le Deu retweeted
In support of a multipolar biopharma world. Why a strong U.S. sector can still thrive next to a stronger China: a BioCentury Guest Commentary by Franck Le Deu buff.ly/5BWbKml














